Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
Elad Jacoby

Elad Jacoby

  • MD
  • Pediatric Hemato-Oncology
  • Pediatric Hematology and Oncology
  • Hebrew
  • English


Dr. Jacoby, the Head of Sheba’s Pediatric Cell Therapy Center, is a recognized global expert in the treatment of childhood leukemia and the application of CAR T-cell therapy. Recognized by Forbes as one of Israel’s best physicians, Dr. Jacoby leads clinical trials in advanced cellular therapies, including CAR T-cell therapy, first-in-human mitochondrial augmentation, and anti-viral T-cells. In addition to his roles at Sheba, Dr. Jacoby is also a senior lecturer at the Tel Aviv University School of Medicine.

Conditions and treatment

  • Leukemia
  • Hematological malignancies
  • Stem cell transplantation
  • Pediatric oncology


  • Head of the Pediatric Cell Therapy Center, Sheba Medical Center
  • Head of the Pediatric Cell Therapy Center, Sheba Medical Center
  • Member, CAR T-cell Taskforce, IBFM Study Group
  • Member, Institutional Review Board, Sheba Medical Center
  • Senior Lecturer, Tel Aviv University School of Medicine

Education and Training

  • Pediatric Hematology and Oncology Fellowship, Johns Hopkins Hospital, Baltimore, USA
  • Clinical and Research Fellowship, National Cancer Institute (NCI), Washington, D.C.
  • Pediatrics Residency, Sheba Medical Center
  • M.D., Tel Aviv University School of Medicine

Board Certifications

  • Pediatrics
  • Pediatric Hematology and Oncology


Early and late hematologic toxicity following CD19 CAR T-cells.

Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, Shimoni A, Nagler A, Toren A, Jacoby E.

Gamma-Delta CAR T-Cells Show CAR-Directed and Independent Activity Against Leukemia.

Rozenbaum M, Meir A, Aharony Y, Itzhaki O, Schachter J, Bank I, Jacoby E, Besser MJ.

Outcomes of first therapy after CD19-CAR T-cell treatment failure in large B-cell lymphoma.

Alarcon Tomas A, Fein JA, Fried S, Flynn JR, Devlin SM, Fingrut WB, Anagnostou T, Alperovich A, Shah N, Fraint E, Lin RJ, Scordo M, Batlevi CL, Besser MJ, Dahi PB, Danylesko I, Giralt S, Imber BS, Jacoby E, Kedmi M, Nagler A, Palomba ML, Roshal M, Salles GA, Sauter C, Shem-Tov N, Shimoni A, Yahalom J, Yerushalmi R, Shah GL, Avigdor A, Perales MA, Shouval R.

Adult Acute Lymphoblastic Leukaemia.

Jacoby E, Gökbuget N, Nagler A.

Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies.

Garcia-Prieto CA, Villanueva L, Bueno-Costa A, Davalos V, González-Navarro EA, Juan M, Urbano-Ispizua Á, Delgado J, Ortiz-Maldonado V, Del Bufalo F, Locatelli F, Quintarelli C, Sinibaldi M, Soler M, Castro de Moura M, Ferrer G, Urdinguio RG, Fernandez AF, Fraga MF, Bar D, Meir A, Itzhaki O, Besser MJ, Avigdor A, Jacoby E, Esteller M.

CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study.

Jacoby E, Ghorashian S, Vormoor B, De Moerloose B, Bodmer N, Molostova O, Yanir AD, Buechner J, Elhasid R, Bielorai B, Rogosic S, Dourthe ME, Maschan M, Rossig C, Toren A, von Stackelberg A, Locatelli F, Bader P, Zimmermann M, Bourquin JP, Baruchel A.

Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study.

Ghorashian S, Jacoby E, De Moerloose B, Rives S, Bonney D, Shenton G, Bader P, Bodmer N, Quintana AM, Herrero B, Algeri M, Locatelli F, Vettenranta K, Gonzalez B, Attarbaschi A, Harris S, Bourquin JP, Baruchel A.

Public Health Nutrition special issue on ultra-processed foods.

Kelly B, Jacoby E.

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A.

Mitochondrial augmentation of hematopoietic stem cells in children with single large-scale mitochondrial DNA deletion syndromes.

Jacoby E, Bar-Yosef O, Gruber N, Lahav E, Varda-Bloom N, Bolkier Y, Bar D, Blumkin MB, Barak S, Eisenstein E, Ahonniska-Assa J, Silberg T, Krasovsky T, Bar O, Erez N, Bielorai B, Golan H, Dekel B, Besser MJ, Pozner G, Khoury H, Jacobs A, Campbell J, Herskovitz E, Sher N, Yivgi-Ohana N, Anikster Y, Toren A.

Request a consultation

Sheba Medical Center provides innovative, personalized medical care to patients from around the world. We are the largest, most comprehensive hospital in the Middle East and dedicated to providing advanced and compassionate medicine for everyone.

We welcome all cases, including the rarest and the most challenging. Our medical teams collaborate to provide the best possible health outcomes. From your initial inquiry through the long-term follow-up care, we are here for you.

Request a consultation and a Sheba Case Manager will contact you shortly: